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Purpose: Experimental studies have suggested that the stromal-derived factor-1 (SDF-1)/CXCR4 axis is associated with tumor 
aggressiveness and metastasis in several malignancies. We performed a meta-analysis to elucidate the relationship between 
CXCR4 expression and the clinicopathological features of prostate cancer.
Materials and Methods: Data were collected from studies comparing Gleason score, T stage, and the presence of metastasis with 
CXCR4 levels in human prostate cancer samples. The studies were pooled, and the odds ratio (OR) of CXCR4 expression for 
clinical and pathological variables was calculated.
Results: Five articles were eligible for the current meta-analysis. We found no relationship between CXCR4 expression and 
Gleason score (＜7 vs. ≥7). The forest plot using the fixed-effects model indicated an OR of 1.585 (95% confidence interval [CI]: 
0.793∼3.171; p=0.193). Further, CXCR4 expression was not associated with the T stage (＜T3 vs. ≥T3), and the relevant 
meta-analysis showed OR=1.803 (95% CI: 0.756∼4.297, p=0.183). However, increased CXCR4 expression was strongly 
associated with metastatic disease with a fixed-effects pooled OR of 7.459 (95% CI: 2.665∼20.878, p＜0.001). 
Conclusions: Our meta-analysis showed that the higher CXCR4 protein expression in prostate cancer specimens is significantly 
associated with the presence of metastatic disease. This supports previous experimental data supporting the role played by the 
SDF-1/CXCR4 axis in metastasis.
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INTRODUCTION
　Prostate cancer is the most commonly diagnosed male 
malignancy and is the second leading cause of cancer 
deaths for men in the Western world [1]. Radical surgery 
or radiotherapy can be curative therapy for patients with 
localized prostate cancer. However, approximately 15% 
to 20% of men with prostate cancer eventually experience 
168   World J Mens Health Vol. 32, No. 3, December 2014
metastatic disease, and androgen deprivation treatment is 
the most effective systemic approach for patients with 
metastatic disease. Although 80% to 90% of patients ini-
tially respond favorably to this treatment, they eventually 
become unresponsive to androgen deprivation and devel-
op castration-resistant prostate cancer (CRPC) and are sub-
sequently at risk of death [2,3]. Serum prostate-specific an-
tigen (PSA) measurements have been used for early de-
tection of prostate cancer, prediction of tumor aggressive-
ness, prognosis, selection of treatment modality, and mon-
itoring of treatment outcomes. Absolute PSA levels and 
other measures of PSA kinetics can be useful in predicting 
bone metastasis, but some limitations remain for the appli-
cation of PSA parameters in various clinical settings. 
Accordingly, much research has been focused on discov-
ering other novel biomarkers that predict the develop-
ment of metastases more accurately [4].
　Stromal derived factor-1 (SDF-1) is a member of the CXC 
subfamily of chemokines that interact with the seven-trans-
membrane G-protein-coupled receptor CXCR4 [5]. CXCR4 
expression has been reported in at least 23 epithelial, mes-
enchymal, and hematopoietic cancers, suggesting the im-
portance of this ligand/receptor axis in tumor aggressive-
ness and metastasis [6]. In addition, the role of the 
SDF-1/CXCR4 axis in prostate cancer has been ex-
perimentally demonstrated. SDF-1 binding to CXCR4 gen-
erates various signaling mechanisms that affect the regu-
lation of angiogenesis, activation of cell invasion, promo-
tion of cell growth, and inhibition of apoptosis, and nota-
bly, plays an important role in organ-specific metastasis 
[7-11]. Several researchers have demonstrated in human 
sample studies that increased CXCR4 expression in prostate 
cancer is associated with tumor aggressiveness, metastatic 
disease, and poor survival outcome [12-18]. However, their 
results were somewhat contradictory and inconclusive be-
cause the number of tested samples in each study was rela-
tively small. Herein, we performed a meta-analysis to eluci-
date the relationship between CXCR4 expression and the 
clinicopathological features of prostate cancer.
MATERIALS AND METHODS
1. Searching strategy
　This meta-analysis was designed and conducted in com-
pliance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement 
(accessible at http://www.prisma-statement.org/) [19]. 
Eligible studies were identified after electronic searching of 
databases. A comprehensive search of the PubMed and 
EMBASE databases was performed using keywords and the 
medical subheadings of ‘CXCR4’ and ‘prostate’. 
Alternative spellings or abbreviations of these keywords 
were also used. There were no research limitations, and the 
most recent study was performed on September 3, 2013.
2. Inclusion and exclusion criteria
　Two investigators (J.Y.L. and D.H.K.) independently se-
lected eligible trials. Studies met the following criteria: (1) 
case-control or cohort studies, (2) immunohistochemical 
studies with human prostate samples to investigate the as-
sociation between CXCR4 and the clinicopathological 
features of prostate cancer including Gleason score, T 
stage, and the existence of metastasis, and (3) published 
full-text articles. Studies without detailed patient data 
were excluded. Disagreement between the two inves-
tigators was solved by discussion with another inves-
tigator (K.S.C.).
3. Data extraction
　One researcher (J.Y.L.) screened the titles and abstracts 
identified by the search strategy. The other two re-
searchers (D.H.K. and H.L.) independently evaluated the 
full text of the papers to determine whether they met the 
inclusion criteria. The databases were designed to ensure 
that the most relevant data were obtained with respect to 
author, publication year, CXCR4 expression, T stage, 
Gleason score, and the presence of metastatic disease. 
Disagreements were resolved by discussion until a con-
sensus was reached or by arbitration employing another 
researcher (K.S.C.).
4. Study quality assessment
　Upon selecting the final group of articles, two re-
searchers (D.H.K. and J.K.K.) independently examined the 
quality of each article by using the Scottish Intercollegiate 
Guidelines Network (SIGN), which is a quality assessment 
tool for observational studies [20]. This system is interna-
tionally accepted and used by guideline developers. 
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Fig. 1. Study selection flow chart. 
The full texts of articles were 
reviewed, and 11 articles were 
selected as potential candidates for
the meta-analysis. Subsequently, 
six articles that did not fit the 
eligibility criteria of this meta- 
analysis were removed. Finally, 
five articles were included in the 
analysis of the relationship be-
tween CXCR4 and the clinico-
pathological features of prostate 
cancer.
Similar rating scales have been published by the Society 
for Prevention Research [21] and Kumpfer and Alvarado 
[22]; however, these require higher levels of evidence 
(when such evidence comes from randomized controlled 
trials or case-control trials performed by multiple in-
dependent research groups) and stricter criteria for assess-
ing the quality of the research [23]. For quality assessment, 
the design quality of a study was categorized as follows: 
‘low’ (score 0∼14); ‘modest’ (score 14.5∼19); ‘good’ 
(score 19.5∼24); or ‘very good’ (score 24.5∼30).
5. Heterogeneity tests
　Heterogeneity among the studies was explored using 
the Q-statistic and Higgins’ I2 statistic [24]. Higgins’ I2 sta-
tistic measures the percentage of total variation due to het-




where ‘Q’ denotes Cochran’s heterogeneity statistic and 
‘df’ indicates the degrees of freedom.
　An I2 value greater than 50% represents substantial 
heterogeneity. For the Q-statistic, heterogeneity was 
deemed significant if p＜0.10 [25]. When there was evi-
dence of heterogeneity, data were analyzed using a ran-
dom-effects model to obtain a summary estimate for the 
test sensitivity with 95% confidence intervals (CIs). In 
studies in which positive results were confirmed, a pooled 
specificity was calculated with 95% CIs.
6. Statistical analyses
　When Q-test values indicated heterogeneity across 
studies (p＜0.10 or I2＞50%), the random-effects model 
was used for the meta-analysis. Otherwise, the fixed-ef-
fects model was employed [26]. Begg and Mazumdar’s 
rank-correlation tests and Egger’s regression intercept test 
were used to examine the evidence of publication bias 
[27,28], which was depicted as a funnel plot (p＜0.05 was 
considered a significant publication bias). A meta-analysis 
of comparable data was performed using R (R version 
3.0.2; R Foundation for Statistical Computing, Vienna, 
Austria; http://www.r-project.org), and its meta and meta-
for packages were used for pair-wise meta-analyses.
RESULTS
1. Quality assessment for eligible studies
　Searching the databases resulted in 141 articles that 
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33  9 24 NA NA NA NA  9 (100.0) 14 (58.3) Low
26  6 20 NA NA  6 (100.0) 11 (55.5) NA NA
Mochizuki 
et al [13]
35 20 15 15 (75.0) 10 (66.7) 16 (80.0) 11 (73.3) 15 (75.0)  6 (0.40) Modest
Xing et al [14] 40 33  7 28 (84.8)  4 (57.1) NA NA 15 (45.5) 0 (0.0) Low
Jung et al [15] 57 36 21 20 (55.6) 13 (61.9) 5 (13.9)  3 (14.3) 10 (27.8) 1 (4.8) Modest
Okera et al 
[16]
55 29 26 27 (93.1) 20 (76.9) 27 (93.1) 23 (88.5) NA NA Low
Values are presented as number only or number (%).
NA: not available.
could be potentially included in our meta-analysis. On the 
basis of the abovementioned inclusion and exclusion cri-
teria, 70 articles were excluded after an evaluation of the 
titles and abstracts. We reviewed the full text of the re-
maining articles, and 11 articles were selected as potential 
candidates for our meta-analysis. Six articles, which did 
not fit the eligibility criteria of this meta-analysis, were 
excluded. Finally, five articles were included in our analy-
sis of the relationship between CXCR4 and the clin-
icopathological features of prostate cancer [12-16] (Fig. 1). 
Data corresponding to confounding factors derived from 
each study are summarized in Table 1. The results of the fi-
nal quality assessment showed that of the five articles in-
cluded, three scored ‘low’ and two were classified as 
‘modest’ according to the SIGN checklists. The most fre-
quent quality assessment issue was poor selection of 
subjects.
2. Heterogeneity assessment
　Heterogeneity was examined using forest plots, as 
shown in Fig. 2. A heterogeneity test showed the follow-
ing: χ2=3.99 with 3 df (p=0.262) and I2=24.9% in the 
analysis of Gleason scores between ＜7 and ≥7; and χ2 
=2.05 with 3 df (p=0.562) and I2=0% in the analysis be-
tween stage ＜T3 and stage ≥T3. In the analysis for meta-
static prostate cancer, a heterogeneity test also demon-
strated homogeneity with χ2=0.19 with 3 df (p=0.86) 
and I2=0%. Because there were no heterogeneities in 
three forest plots, fixed-effects models were applied using 
the Mantel-Haenszel method. The radial plots revealed no 
heterogeneous variables after the selection of effects mod-
els (Fig. 3).
3. Assessment for publication bias
　Begg and Mazumdar’s rank-correlation tests revealed 
no evidence of publication bias between Gleason scores 
of ＜7 and ≥7 in the present meta-analysis (p=0.333). 
With respect to T stage and metastasis, a significant pub-
lication bias was observed (p=0.083 in two meta-analy-
ses). However, Egger’s regression intercept test also re-
vealed no evidence of publication bias in two meta-analy-
ses for T stage (p=0.171) and metastasis (p=0.400). Using 
the results of these three meta-analyses, we drew the fun-
nel plot shown in Fig. 4.
4. Comparison of CXCR4 expression according to 
prostate cancer Gleason score, T stage, and 
metastasis
　We observed no relationship in a meta-analysis regard-
ing CXCR4 expression and Gleason score (＜7 vs. ≥7). 
The forest plot using the fixed-effects model demonstrated 
an odds ratio (OR) of 1.585 (95% CI: 0.793∼3.171, 
p=0.193). Additionally, CXCR4 expression was not asso-
ciated with T stage (＜T3 vs. ≥T3), and the relevant 
meta-analysis showed an OR of 1.803 (95% CI: 0.756∼
4.297, p=0.183). However, higher CXCR4 expression 
was strongly associated with the presence of metastatic 
disease, with a fixed-effects pooled OR of 7.459 (95% CI: 
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Fig. 2. Forest plot of high versus low expression of CXCR4. (A) There is no relationship between CXCR4 expression and Gleason scores
(GS; ＜7 vs. ≥7) according to the meta-analysis. (B) CXCR4 expression is not associated with T stage (＜T3 vs. ≥T3), and the relevant
meta-analysis showed an odds ratio (OR) of 1.803 (95% confidence interval (CI): 0.756∼4.297; p=0.183). (C) Higher CXCR4 
expression was strongly associated with the presence of metastatic disease, with a fixed-effects pooled OR of 7.459 (95% CI: 2.665∼
20.878; p＜0.001). W: weight.
2.665∼20.878, p＜0.001).
DISCUSSION
　The data from this meta-analysis indicated that in-
creased CXCR4 protein expression in prostate cancer 
specimens is significantly associated with the presence of 
metastatic disease, but not with Gleason scores or T stage. 
The SDF-1/CXCR4 axis has been experimentally shown to 
play an important role in organ-specific metastasis of pros-
tate cancer, and several studies with human samples have 
compared tumor aggressiveness, metastatic disease, and 
survival outcome with CXCR4 expression levels. However, 
the numbers of samples tested in each study were too 
small to achieve adequate statistical power. For example, 
there were four studies in this meta-analysis evaluating 
CXCR4 expression and metastasis. However, the study by 
Mochizuki et al [13] was the only study to demonstrate 
with statistical significance that higher CXCR expression is 
associated with metastatic disease. Although the other 
three studies revealed similar tendencies, their results 
were statistically not significant, predominantly due to the 
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Fig. 3. Radial plots indicated no heterogeneity after selection of 
effects models for all studies. CXCR4 expression and Gleason 
score (A), CXCR4 expression and T stage (B), and CXCR4 
expression and metastasis (C).
small sample sizes [12,14,15]. Thus, our meta-analysis 
provides meaningful clinical and pathological evidence 
that strongly supports previous experimental data regard-
ing the role of the SDF-1/CXCR4 axis in prostate cancer 
metastasis. However, our analysis was limited by the small 
number of included studies.
　It is known that the binding of chemokines to their G 
protein-linked receptors on target cells leads to a series of 
signal transduction events involving the generation of in-
ositol 1, 4, 5-triphosphate and cyclic adenosine mono-
phosphate-dependent protein kinase, activation of phos-
phatidylinositol 3-kinase (PI3K), phosphorylation of pro-
tein kinase B (Akt), phosphorylation of extracellular sig-
nal-regulated kinase (ERK), elevation of components of fo-
cal adhesion complexes, and activation of protein kinase 
C [29]. SDF-1 binding to CXCR4 generates various signal-
ing mechanisms that regulate angiogenesis, activate cell 
invasion, promote cell growth, inhibit apoptosis, and no-
tably, play an important role in organ-specific metastasis. 
In a previous study on prostate cancer, differential activa-
tion of the ERK and PI3K/Akt pathways resulted in differ-
ential secretion of interleukin (IL)-6, IL-8, tissue inhibitors 
of metalloproteinase-2, and vascular endothelial cell 
growth factor (VEGF), which affected the ability of the can-
cer cells to induce angiogenesis [7]. Exogenous SDF-1 in-
duces Akt phosphorylation in PC-3 cells, which is in-
dependent of PI3K and indispensable for matrix metal-
loproteinase (MMP)-9 secretion, migration, and invasion 
[8]. SDF-1 induction enhances various MMPs in PC-3 cells 
[9]. It has also been reported that SDF-1-induced ex-
pression of CXCR4 in PC-3 cells is dependent on the mi-
togen-activated protein Kinase Kinase (MEK)/ERK signal-
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Fig. 4. Funnel plots demonstrated no publication bias in this 
meta-analysis for all studies. CXCR4 expression and Gleason 
score (A), CXCR4 expression and T stage (B), and CXCR4 
expression and metastasis (C).
ing cascade and on nuclear factor kappa B (NF-κB) activa-
tion, which enhances endothelial adhesion and trans-
endothelial migration [10]. Additionally, Wang et al [11] 
showed that CXCR4 plays an important role in prostate 
cancer metastasis via the up-regulation of VEGF.
　Androgen deprivation therapy is effective as an initial 
strategy in the management of metastatic prostate cancer; 
however, it generally fails to obtain long-lasting efficacy. 
Thus, metastatic prostate cancer becomes CRPC, which is 
no longer responsive to hormonal manipulation. 
Unfortunately, there are no effective treatment modalities 
for the management of CRPC. The combination of doce-
taxel and prednisone has been regarded as standard 
first-line therapy for CRPC during the past decades, but the 
survival gain from docetaxel chemotherapy is limited and 
unsatisfactory [30]. There have been great efforts to dis-
cover new molecular targets and develop novel agents 
based on the advanced understanding of prostate cancer 
biology. Researchers and physicians have focused on 
treatment strategies targeting steroidogenesis, androgen 
receptor, angiogenesis, other growth and survival path-
ways, and immune response [31]. Recently, novel drugs 
have been approved for CRPC patients. Sipuleucel-T, cab-
azitaxel, abiraterone acetate, radium-223, and enzaluta-
mide have shown improved overall survival outcomes in 
randomized phase III trials; nevertheless, metastatic CRPC 
still remains incurable [31].
　Because metastasis greatly influences the prognosis and 
treatment of advanced prostate cancer, targeting the 
SDF-1/CXCR4 axis is a potentially attractive strategy be-
cause it emphasizes prevention or delay of metastatic 
disease. Recent studies have shown promising ex-
perimental data, suggesting that CXCR4 antagonism can 
be an effective modality to control metastatic disease by 
disrupting the interaction between cancer cells and the 
protective microenvironment [32,33]. Domanska et al 
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[32] reported that CXCR4 inhibition sensitizes prostate 
cancer cells to docetaxel in vitro and in vivo. Cho et al [33] 
found that CXCR4 antagonism significantly inhibited mi-
crovessel formation and tumor growth in the PC-3 tumor 
xenograft model as compared to control tumors. In other 
xenograft models, such as anaplastic thyroid cancer, ovar-
ian cancer, and oral squamous cell cancer, inhibitory ef-
fects of CXCR4 antagonism on tumor growth and meta-
stasis have been demonstrated [33]. Recently, several 
CXCR4 antagonists have been developed to block the 
SDF-1/CXCR4 axis and are at different stages of develop-
ment [34]. The first-in-class CXCR4 antagonist, plerixafor 
(AMD3100), was approved by the United States Food and 
Drug Administration in 2008 for the mobilization of hem-
atopoietic stem cells. Several other drugs are also cur-
rently in clinical trials. CXCR4 antagonists such as plerix-
afor, TG-0054, AMD070, MSX-122, CTCE-9908, and 
POL6326 are under investigation in phase I/II clinical trials 
for patients with cancer, human immunodeficiency virus, 
and myelokathexis [34].
　The current meta-analysis provides further evidence of 
the relationship between CXCR4 expression and meta-
stasis in prostate cancer. Increased CXCR4 expression in 
prostatectomy specimens could be a useful predictor of 
poor prognosis, with a relatively high probability of meta-
stasis or the future development of metastatic disease. In 
addition, preclinical studies have suggested that blocking 
the SDF-1/CXCR4 interaction alone or in combination with 
other therapeutic modalities might be a potential strategy 
for metastatic prostate cancer. Taken together, results from 
phase I/II clinical trials evaluating efficacy and data regard-
ing the safety of the available CXCR4 antagonists are prom-
ising for patients with advanced prostate cancer.
CONCLUSIONS
　The present meta-analysis showed that increased 
CXCR4 protein expression in prostate cancer specimens is 
significantly associated with the presence of metastatic 
disease. However, CXCR4 expression was not associated 
with Gleason scores or T stage. Our meta-analysis results 
strongly support previous experimental data highlighting 
the role of the SDF-1/CXCR4 axis in prostate cancer 
metastasis.
ACKNOWLEDGEMENTS
　This study was supported by a faculty research grant 
from the Yonsei University College of Medicine for 2010 
(6-2010-0070).
REFERENCES
1. Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, et al. 
Charlson comorbidity index is an important prognostic fac-
tor for long-term survival outcomes in Korean men with 
prostate cancer after radical prostatectomy. Yonsei Med J 
2014;55:316-23.
2. Leuprolide versus diethylstilbestrol for metastatic prostate 
cancer. The Leuprolide Study Group. N Engl J Med 1984; 
311:1281-6.
3. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 
324:236-45.
4. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, 
Ficarra V, et al. Predicting the risk of bone metastasis in 
prostate cancer. Cancer Treat Rev 2014;40:3-11.
5. Wells TN, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, 
Cooke RM, Chung CW, et al. Selectivity and antagonism of 
chemokine receptors. J Leukoc Biol 1996;59:53-60.
6. Furusato B, Mohamed A, Uhlén M, Rhim JS. CXCR4 and 
cancer. Pathol Int 2010;60:497-505.
7. Wang J, Wang J, Sun Y, Song W, Nor JE, Wang CY, et al. 
Diverse signaling pathways through the SDF-1/CXCR4 che-
mokine axis in prostate cancer cell lines leads to altered 
patterns of cytokine secretion and angiogenesis. Cell Signal 
2005;17:1578-92.
8. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil 
RD, et al. CXCL12/CXCR4 signaling activates Akt-1 and 
MMP-9 expression in prostate cancer cells: the role of bone 
microenvironment-associated CXCL12. Prostate 2006;66: 
32-48.
9. Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12- 
CXCR4 interactions modulate prostate cancer cell migra-
tion, metalloproteinase expression and invasion. Lab Invest 
2004;84:1666-76.
10. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal 
KC. Up-regulation of CXCR4 expression in PC-3 cells by 
stromal-derived factor-1alpha (CXCL12) increases endothe-
lial adhesion and transendothelial migration: role of MEK/ 
ERK signaling pathway-dependent NF-kappaB activation. 
Cancer Res 2005;65:9891-8.
11. Wang Q, Diao X, Sun J, Chen Z. Regulation of VEGF, 
MMP-9 and metastasis by CXCR4 in a prostate cancer cell 
line. Cell Biol Int 2011;35:897-904.
12. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal 
B, Karplus R, et al. Role of high expression levels of CXCR4 
in tumor growth, vascularization, and metastasis. FASEB J 
2004;18:1240-2.
Joo Yong Lee, et al: CXCR4 Expression and Metastasis in Prostate Cancer   175
13. Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, 
Yasumoto H, Dahiya R, et al. Interaction of ligand-receptor 
system between stromal-cell-derived factor-1 and CXC che-
mokine receptor 4 in human prostate cancer: a possible pre-
dictor of metastasis. Biochem Biophys Res Commun 2004; 
320:656-63.
14. Xing Y, Liu M, Du Y, Qu F, Li Y, Zhang Q, et al. Tumor 
cell-specific blockade of CXCR4/SDF-1 interactions in pros-
tate cancer cells by hTERT promoter induced CXCR4 knock-
down: A possible metastasis preventing and minimizing 
approach. Cancer Biol Ther 2008;7:1839-48.
15. Jung SJ, Kim CI, Park CH, Chang HS, Kim BH, Choi MS, et 
al. Correlation between chemokine receptor CXCR4 ex-
pression and prognostic factors in patients with prostate 
cancer. Korean J Urol 2011;52:607-11.
16. Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov 
H, et al. Evaluation of nuclear factor κB and chemokine re-
ceptor CXCR4 co-expression in patients with prostate can-
cer in the Radiation Therapy Oncology Group (RTOG) 
8610. BJU Int 2011;108:E51-8.
17. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse 
H. Chemokine receptor CXCR4 expression and prognosis in 
patients with metastatic prostate cancer. Cancer Sci 2008; 
99:539-42.
18. de Muga S, Hernández S, Salido M, Lorenzo M, Agell L, 
Juanpere N, et al. CXCR4 mRNA overexpression in high 
grade prostate tumors: lack of association with TMPRSS2- 
ERG rearrangement. Cancer Biomark 2012-2013;12:21-30.
19. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. 
Preferred reporting items for systematic reviews and meta- 
analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
20. Keaney M, Lorimer AR. Auditing the implementation of 
SIGN (Scottish Intercollegiate Guidelines Network) clinical 
guidelines. Int J Health Care Qual Assur Inc Leadersh 
Health Serv 1999;12:314-7.
21. Flay BR, Biglan A, Boruch RF, Castro FG, Gottfredson D, 
Kellam S, et al. Standards of evidence: criteria for efficacy, 
effectiveness and dissemination. Prev Sci 2005;6:151-75.
22. Kumpfer KL, Alvarado R. Family-strengthening approaches 
for the prevention of youth problem behaviors. Am Psychol 
2003;58:457-65.
23. Bröning S, Kumpfer K, Kruse K, Sack PM, Schaunig-Busch I, 
Ruths S, et al. Selective prevention programs for children 
from substance-affected families: a comprehensive system-
atic review. Subst Abuse Treat Prev Policy 2012;7:23.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring 
inconsistency in meta-analyses. BMJ 2003;327:557-60.
25. Fleiss JL. Analysis of data from multiclinic trials. Control 
Clin Trials 1986;7:267-75.
26. DerSimonian R, Kacker R. Random-effects model for 
meta-analysis of clinical trials: an update. Contemp Clin 
Trials 2007;28:105-14.
27. Begg CB, Mazumdar M. Operating characteristics of a rank 
correlation test for publication bias. Biometrics 1994;50: 
1088-101.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in 
meta-analysis detected by a simple, graphical test. BMJ 
1997;315:629-34.
29. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, 
Janowska-Wieczorek A, et al. Trafficking of normal stem 
cells and metastasis of cancer stem cells involve similar 
mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem 
Cells 2005;23:879-94.
30. Wirth MP. Hormone-refractory prostate cancer: what have 
we learned? BJU Int 2007;100 Suppl 2:56-9.
31. Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M. 
Targeting metastatic castration-resistant prostate cancer: 
mechanisms of progression and novel early therapeutic 
approaches. Expert Opin Investig Drugs 2014;23:469-87.
32. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude 
Munnink TH, Kruizinga RC, Ananias HJ, et al. CXCR4 in-
hibition with AMD3100 sensitizes prostate cancer to doce-
taxel chemotherapy. Neoplasia 2012;14:709-18.
33. Cho KS, Yoon SJ, Lee JY, Cho NH, Choi YD, Song YS, et al. 
Inhibition of tumor growth and histopathological changes 
following treatment with a chemokine receptor CXCR4 an-
tagonist in a prostate cancer xenograft model. Oncol Lett 
2013;6:933-8.
34. Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small 
molecule inhibitors of CXCR4. Theranostics 2013;3:47-75.
